摩根士丹利研究报告指将中国中药2025至30年的盈利预测下调8%至13%因配方颗粒业务进一步减价以致毛利率下降以及销售额

智通财经
27 Jun
摩根士丹利研究报告指将中国中药2025至30年的盈利预测下调8%至13%因配方颗粒业务进一步减价以致毛利率下降以及销售额下跌。该行亦考虑到额外的减值损失以及补缴税款并认为趋势会自2024年起持续下去。该行对其目标价由1.7港元降至1.6港元评级“减持”。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10